Release Date: June 4, 2022
Expiration Date: June 4, 2023
Activity Overview
This educational activity is an archive of the live virtual presentation held on June 3, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists, pulmonologists, pathologists, surgeons, nurses, pharmacists, and other oncology healthcare professionals.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine actionable biomarkers that are key to inform clinical decision-making in the management of advanced forms of NSCLC
- Explain the role of testing and methods to facilitate the application of diagnostic approaches in NSCLC treatment settings
- Describe efficacy and safety results from investigations that utilized actionable biomarkers to personalize care among patients with NSCLC
- Evaluate emerging therapeutic targets and biomarker-driven strategies undergoing late-stage evaluation for use among patients with advanced NSCLC
Charu Aggarwal, MD, MPH
Leslye M. Heisler Associate Professor of Medicine
Associate Director, Penn Center for Precision Medicine
Physician Leader, Airways Malignancies Clinical Research
University of Pennsylvania
Philadelphia, PA
Disclosures: Grant/Research Support: Recipient- Institution: AstraZeneca/ MedImmune Genentech/ Roche, Incyte, MacroGenics, Merck Sharp & Dohme; Consultant: AstraZeneca, Blueprint Genetics, Boehringer lngelheim, Celgene, Daiichi Sankyo/ Regeneronl Sanofi , Eisai, Genentech, Janssen, Lilly, Merck, NalGene, Pfizer, Shionogi, Turning Point Therapeutics.
Dara Aisner MD, PhD
Associate Professor of Pathology
Medical Director, Colorado Molecular Correlates Laboratory
University of Colorado Anschutz Medical Campus
Aurora, CO
Disclosures: Grant/Research Support: Genentech; Consultant: Genentech, Blueprint Medicines, Loxo Oncology, Sanofi Genzyme.
D. Ross Camidge, MD, PhD
Professor, Division of Medical Oncology
Joyce Zeff Chair in Lung Cancer Research
University of Colorado Denver School of Medicine
Denver, CO
Disclosures: Grant/Research Support: Inivata; Consultant: 2022: Appolomics (SRC), AstraZeneca/Daiichi (ILD adjudication committee), BeiGene (DSMB) EMD Serono, Medtronic, Mersana (ILD adjudication committee), Mirati, Onkure, Roche 2021: AbbVie, Amgen, AnHeart, Apollomics (SRC), AstraZeneca (SRC/SC), BeiGene (DSMC), Bio-Thera (DSMB), Blueprint, Daiichi-Sankyo (ILD adjudication committee), Elevation (SRC), Eli Lilly (DSMB and NCCN), EMD Serono, Helsinn (DSMB), Hengrui (DSMC), Janssen, Kestrel (SAB, Shares), Mersana, Nuvalent (SAB), Puma (NCCN), Ribon, Roche/Genentech, Sanofi , Seattle Genetics, Takeda, Turning Point 2020: Amgen, Anchiarno (SAB), Apollomics (SRC), AstraZeneca, Bio-Thera (DSMB), BMS, Daiichi-Sankyo (ILD adjudication committee), Eisai, EMD Serono, Elevation (SRC), Eli Lilly, GSK, Helssin, Janssen, Mersana, Onkure, Pfi zer, Qilu, Roche, Sanofi, Seagen, Takeda; Other: Company sponsored trials at institution (PI roles): 2020-22: AbbVie, AstraZeneca, Blueprint, Dizal, Inhibrx, Karyopharm, Pfi zer, Phosplatin, PsiOxus, Rain, Roche/Genentech, Seattle Genetics, Takeda, Turning Point, Verastem.
Balazs Halmos, MD, MS
Professor of Clinical Medicine
Director, Thoracic/Head and Neck Oncology
Director, Clinical Cancer Genomics
Albert Einstein College of Medicine/Montefi ore Medical Center
Bronx, NY
Disclosures: Grant/Research Support: AbbVie, Advaxis, Amgen, AstraZeneca, Boehringer-Ingelheim, Daiichi, GSK, Janssen, Jazz, Merck, Novartis; Consultant: Apollomics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech/Roche, Lilly, Merck, Novartis, Pfi zer, Takeda, TPT Therapeutics, Veracyte.
Julia Kathleen Rotow, MD
Instructor in Medicine
Dana-Farber Cancer Institute
Boston MA
Disclosures: Consultant: AstraZeneca, AbbVie, Gritstone, Lilly, Sanofi-Genzyme, Takeda, Genentech; Other: Honoraria from Chiatai Tianqing, AstraZeneca, Pfizer, Janssen, Sanofi-Genzyme, Jazz, Lilly.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies, with the following exception (Jennifer Hilton, RN, BSN, associate medical director: Former Consultant: Medtronic; GoCatalant/Pfizer).
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
